Dudediligence.

Merck & Co., Inc

MRKNYSE · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$16.66BSep ’24$15.62BDec ’24$15.53BMar ’25$15.81BJun ’25$17.28BSep ’25$16.40BDec ’25$16.29BMar ’26$16.61BJun ’26
Net income, by quarter
$3.16BSep ’24$3.74BDec ’24$5.08BMar ’25$4.43BJun ’25$5.79BSep ’25$2.96BDec ’25−$4.24BMar ’26−$1.33BJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$48.70B$59.28B$60.12B$64.17B$65.01B
Gross profit$35.08B$41.87B$43.99B$48.98B$48.63B
Net income$13.05B$14.52B$365.0M$17.12B$18.25B
Operating cash flow$13.12B$19.09B$13.01B$21.47B$16.47B
Free cash flow$8.67B$14.71B$9.14B$18.10B$12.36B
Cash$8.10B$12.69B$6.84B$13.24B$14.56B
Debt$33.10B$30.69B$35.05B$37.11B$49.34B
Shares outstanding3.58B3.58B3.58B3.58B3.58B